Cleared Traditional

K811787 - QUANTAPHASE T-4 RIA

K811787 is an FDA 510(k) clearance for QUANTAPHASE T-4 RIA, manufactured by Bio-Rad. The device is a Class 2 Chemistry device with product code CDX cleared through the Traditional 510(k) pathway after a 17-day FDA review.

Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 1981
Decision
17d
Days
Class 2
Risk

K811787 is an FDA 510(k) clearance for the QUANTAPHASE T-4 RIA. Classified as Radioimmunoassay, Total Thyroxine (product code CDX), Class II - Special Controls.

Submitted by Bio-Rad (Mchenry, US). The FDA issued a Cleared decision on July 10, 1981 after a review of 17 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1700 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Bio-Rad devices

FDA 510(k) Submission Details - K811787

510(k) Number K811787 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received June 23, 1981
Decision Date July 10, 1981
Days to Decision 17 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
71d faster than avg
Panel avg: 88d · This submission: 17d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

CDX Device Classification - Class 2, Special Controls

Product Code CDX Radioimmunoassay, Total Thyroxine
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1700
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - CDX Radioimmunoassay, Total Thyroxine

All 93
Devices cleared under the same product code (CDX) and FDA review panel - the closest regulatory comparables to K811787.
SPAC T4 RIA TEST KIT
K820725 · Mallinckrodt Critical Care · Jun 1982
ENDAB T4 ENZYME IMMUNOASSAY KIT
K821141 · Immunotech Corp. · May 1982
THYROXINE T4 KIT
K820886 · Pcl-Ria, Inc. · Apr 1982
COAT-A-COUNT T4 RIA KIT
K811315 · Diagnostic Products Corp. · May 1981
125 I-T4 RIA TEST KIT
K811070 · Intl. Immunoassay Laboratories, Inc. · Apr 1981
IMMU-TRACE T4 RIA PROCEDURE
K803046 · American Dade · Jan 1981